Division of Medical Oncology, University of Colorado - Denver, 12801 E 17th Avenue, Mailstop 8117, Aurora, CO 80045, USA.
Expert Opin Pharmacother. 2010 Apr;11(5):807-16. doi: 10.1517/14656561003641982.
The role of estrogen deprivation for the treatment of breast cancer has been understood since the 1800s. Pharmacologic advances in the field in the past decades, including tamoxifen and the aromatase inhibitors, have contributed significantly to the reduced mortality of estrogen-sensitive breast cancer. However, this subtype of breast cancer still presents with relapses and, once metastatic, progression to hormone-refractory state and loss of disease control remain an expected disease course. Fulvestrant, a pure estrogen receptor downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002. Its unique mechanism of action offers potential advantages over other estrogen targeted therapies.
Published scientific literature, including presented abstracts, on fulvestrant from 1985 to the present were reviewed with selected publications included.
This review addresses current issues and therapies for estrogen-sensitive breast cancer, highlights the role of fulvestrant in current treatment guidelines and outlines some of the ongoing investigations of this compound.
Fulvestrant is an effective and well-tolerated drug for treatment of metastatic estrogen-sensitive breast cancer. Work is underway to enhance its clinical benefit to patients as a single agent and in combination with other therapies.
自 19 世纪以来，人们就已经了解雌激素剥夺在乳腺癌治疗中的作用。过去几十年中，该领域的药理学进展，包括他莫昔芬和芳香酶抑制剂，极大地降低了雌激素敏感型乳腺癌的死亡率。然而，这种乳腺癌亚型仍会复发，一旦发生转移，激素难治状态的进展和疾病控制的丧失仍然是预期的疾病进程。氟维司群是一种纯雌激素受体下调剂，自 2002 年获得 FDA 批准以来，是抗雌激素治疗手段的新成员。其独特的作用机制为其提供了优于其他雌激素靶向治疗的潜在优势。
本综述回顾了自 1985 年至今发表的关于氟维司群的科学文献，包括已发表的摘要，并选择了一些有代表性的出版物进行介绍。
本综述讨论了雌激素敏感型乳腺癌的当前问题和治疗方法，强调了氟维司群在当前治疗指南中的作用，并概述了该化合物的一些正在进行的研究。
氟维司群是一种有效且耐受性良好的治疗转移性雌激素敏感型乳腺癌的药物。目前正在努力提高其作为单一药物以及与其他疗法联合使用的临床获益。
